ArticleBlood advances2018
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.Blood advances · 2021Trial
- Trial
- Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.Bone marrow transplantation · 2026Article
- Sarcopenia-associated CD8Annals of hematology · 2026Article
- Article
- Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.British journal of cancer · 2026Article
- A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation.Blood and lymphatic cancer : targets and therapy · 2026Article
- Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.Bone marrow transplantation · 2026Article
- T Cell immune reconstitution after allo-HSCT: key factors and implications.Blood science (Baltimore, Md.) · 2025Review
- Early CD4 + T cell immune reconstitution as a biomarker for Epstein-Barr virus control following allogeneic transplantation.Blood research · 2025Article
- Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.Bone marrow transplantation · 2025Article
- Immune Monitoring after Cell Therapy and Hematopoietic Cell Transplantation: Guidelines by the ISCT Stem Cell Engineering Committee.Cytotherapy · 2025Review
- Indirect presentation of mismatched human leukocyte antigen-B associates with outcomes of cord blood transplantation.British journal of haematology · 2025Article
- Relevance of Recent Thymic Emigrants Following Allogeneic Hematopoietic Cell Transplantation for Pediatric Patients with Inborn Errors of Immunity.Transplantation and cellular therapy · 2025Article
- Article
- Targeting hypoxia-inducible factor 1α in chronic graft-versus-host disease to enhance graft-versus-leukemia responses: implications for nanotherapeutics.Frontiers in immunology · 2025Review
- Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation.International journal of hematology · 2025Article
- Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.Advances in experimental medicine and biology · 2025Review
- Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.Annals of hematology · 2024Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Slow immune reconstitution is a major obstacle to the successful use of allogeneic hematopoietic cell transplantation (allo-HCT). As matched sibling donor (MSD) allo-HCT is regarded as the gold standard, we evaluated the pace of immune reconstitution in 157 adult recipients of reduced-intensity conditioning followed by MSD peripheral blood HCT (n = 68) and compared these to recipients of umbilical cord blood (UCB; n = 89). At day 28, UCB recipients had fewer natural killer (NK) cells than MSD recipients, but thereafter, NK cell numbers (and their subsets) were higher in UCB recipients. During the first 6 months to 1 year after transplant, UCB recipients had slower T-cell subset recovery, with lower numbers of CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.